Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, R&D spend, and cash-runway figures in Arcutis Biotherapeutics (ARQT) SEC documents can stretch across hundreds of pages. If you need to know how ZORYVE sales offset development costs or where the next PDE4 program stands, wading through every quarterly update is time-consuming and complex.
Stock Titan solves this problem with AI-powered summaries that turn raw disclosures into plain-English takeaways. Whether you are searching for “Arcutis quarterly earnings report 10-Q filing,” want “Arcutis insider trading Form 4 transactions,” or need an “Arcutis proxy statement executive compensation” breakdown, our engine surfaces the exact paragraph in seconds. Real-time alerts appear the moment an “Arcutis Form 4 insider transactions real-time” notice hits EDGAR, while cross-links let you compare each metric historically for quick “Arcutis earnings report filing analysis.”
Dive deeper without the jargon: jump straight to liquidity tables in the “Arcutis annual report 10-K simplified,” scan risk-factor changes, or review pivotal Phase 3 data inside an “Arcutis 8-K material events explained” filing. Many professionals rely on us for “understanding Arcutis SEC documents with AI” because our platform highlights option-exercise patterns under “Arcutis executive stock transactions Form 4,” flags non-recurring charges, and maps clinical timelines to projected market launches. With comprehensive coverage of every 10-K, 10-Q, 8-K, S-1, and Form 4, plus clear explanations, complex immuno-dermatology disclosures finally make sense.
Arcutis Biotherapeutics (ARQT) director Neha Krishnamohan reported option exercises and share sales. On 11/13/2025, she exercised stock options to acquire 27,052 shares at $8.63 and 12,220 shares at $7.51 per share, then sold 39,272 shares at a weighted average price of $23.1896 and an additional 1,232 shares at $23.37.
After these transactions, she directly owned 22,123 shares of Arcutis common stock. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, with an end date of November 2, 2026, which is designed to allow insiders to sell shares according to a preset schedule.
Arcutis Biotherapeutics, Inc. (ARQT) director Keith Leonard reported a charitable gift of company stock. On 11/13/2025, he transferred 4,312 shares of Arcutis common stock in a transaction coded as a gift at a stated price of $0, described as a transfer to a Charitable Remainder Unitrust. After this transaction, he reported owning 22,123 shares directly. He also reported 1,750 shares held indirectly through the Leonard Family Trust dated August 28, 1996, for which he serves as a trustee and disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics (ARQT): Reporting person Larry Todd Edwards, EVP Chief Commercial Officer, reported an open-market sale of 29,131 shares of common stock on 11/06/2025 at a weighted average price of $25.1597. The filing notes multiple trades within a $25.00–$25.2600 range.
Following the transaction, the reporting person beneficially owns 150,193 shares, held directly. The filer undertakes to provide detailed trade-by-trade information upon request, as customary for weighted-average disclosures.
Arcutis Biotherapeutics (ARQT) insider transaction: On 11/06/2025, the company’s Executive Vice President and Chief Medical Officer exercised stock options for 17,250 shares at $3.64 and sold 17,250 common shares at a weighted average price of $24.1823, with trades executed between $23.79 and $24.4493. The transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
Following these transactions, the reporting person beneficially owned 98,325 shares of common stock and 155,250 derivative securities (options). The reported option grant vests monthly over four years from January 12, 2024, until fully vested on the fourth anniversary.
Arcutis Biotherapeutics (ARQT) filed a Form 4 reporting insider stock sales. Executive Vice President and Chief Medical Officer Patrick Burnett reported selling 2,607 shares of common stock on 11/03/2025 at a weighted average price of $24.7124 and 15 shares at $25.4. He also sold 3,864 shares on 11/05/2025 at a weighted average price of $23.7172. Following these transactions, he beneficially owned 98,325 shares directly.
The 11/03/2025 sale was made to cover tax withholding obligations tied to vesting Restricted Stock Units. The 11/05/2025 transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
Arcutis Biotherapeutics (ARQT) director Howard G. Welgus sold 10,000 shares of common stock on 11/03/2025 under a Rule 10b5-1 trading plan. The weighted average sale price was $25.2669, with individual trades ranging from $25.10 to $25.4298.
Following the sale, he beneficially owned 89,744 shares, held directly. The 10b5-1 plan was adopted on March 11, 2025 and has an end date of May 29, 2026.
Arcutis Biotherapeutics (ARQT) reported an insider transaction by its SVP Chief Financial Officer. On 11/03/2025, the officer sold 88 shares of common stock at a weighted average price of $24.7185, as noted in the filing.
The footnote states the sale was made to cover tax withholding upon the vesting of Restricted Stock Units. Following the transaction, the officer beneficially owned 64,927 shares directly. The trades occurred in multiple lots between $24.435 and $25.31.
Arcutis Biotherapeutics (ARQT) reported insider activity by its President, Chief Executive Officer, and Director. On November 3, 2025, the reporting person sold 11,547 shares of common stock to cover tax withholding obligations tied to the vesting of restricted stock units.
The sales occurred at weighted-average prices of $24.7122 and $25.3991. Following these transactions, the reporting person directly owned 794,893 shares. Additional indirect holdings were reported, including 124,956 shares held by a trust and 57,358 shares held by an LLC, along with other trust-held positions.
Arcutis Biotherapeutics (ARQT) insider transaction: An officer sold shares on 11/03/2025 primarily to cover tax withholding tied to RSU vesting. The filing reports two sales: 7,165 shares at a weighted average price of $24.7123 and 43 shares at a weighted average price of $25.3985. Following these transactions, the reporting person directly held 154,026 shares. The reporting person’s title is SVP General Counsel and Corporate Secretary.
Arcutis Biotherapeutics (ARQT): President and CEO Todd Franklin Watanabe reported selling 40,000 shares of common stock on 10/28/2025 at a weighted average price of $25.0258, with individual trades ranging from $25.00 to $25.1691. The sale was made under a Rule 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026.
Following the transaction, he beneficially owns 806,440 shares directly. Indirect holdings include 25,410 shares by The John Franklin Watanabe Trust, 25,410 shares by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares by Watanabe Ventures, LLC, and 124,956 shares by The Watanabe 2016 Irrevocable Trust.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
